Outcomes of Hemospray therapy in the treatment of intraprocedural upper gastrointestinal bleeding post-endoscopic therapy.

ABSTRACT:

Introduction

With increasing advances in minimally invasive endoscopic therapies and endoscopic resection techniques for luminal disease, there is an increased risk of post-procedure bleeding. This can contribute to significant burden on patient's quality of life and health resources when reintervention is required. Hemospray (Cook Medical, North Carolina, USA) is a novel haemostatic powder licensed for gastrointestinal bleeding. The aim of this single-arm, prospective, non-randomised multicentre international study is to look at outcomes in patients with upper gastrointestinal bleeds following elective endoscopic therapy treated with Hemospray to achieve haemostasis.

Methods

Data was prospectively collected on the use of Hemospray from 16 centres (January 2016-November 2019

SUBMITTER: Hussein M 

PROVIDER: S-EPMC7724526 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature